References
- Bryskier A, Agouridas C, Chantot JF. Acid stability of new macrolides. J Chemother 1993; 5 (Suppl 1): 158–9.
- Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000; 36: 183–93.
- Reinert RR, Bryskier A, Lutticken R. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother 1998; 42: 1509–11.
- Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 1515–6.
- Schulin T, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulous GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42: 1520–3.
- Barry AL, Fuchs PC, Brown SD. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dal-fopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998; 42: 945–6.
- Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42: 624–30.
- Lenfant B, Sultan E, Wable C, Pascual MH, Meyer BH, Scholtz HE. Pharmacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers. Abstract A-49. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA, 24–27 September 1998.
- Chu S, Park Y, Locke C, Wilson DS, Cavanaugh JC. Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial. J Clin Pharmacol 1992; 32: 32–6.
- Foulds G, Luke DR, Teng R, Willavize SA, Freidman H, Curatolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996; 37 (Suppl C): 37–44.
- Rutland J, Berned N, Marlin GE. The influence of food on the bioavailability of new formulations of erythromycin stearate and base. Br J Clin Pharmacol 1979; 8: 343–7.
- Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 2000; 28: 72–8.
- Diletti E, Hauschke P, Steinijans VW. Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int J Clin Pharmacol Ther Toxicol 1992; 30 (Suppl 1): 59–62.
- Namour R, Wessels DH, Pascual MH, Reynolds E, Sultan E, Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) after ascending single dose and multiple doses. Antimicrob Agents Chemother 2001; 45: 170–5.